Regulatory approval of photoimmunotherapy: photodynamic therapy that induces immunogenic cell death.
Cetuximab saratolacan
EGFR
head and neck cancer
immunogenic cell death
photosensitizer IR700
Journal
Oncoimmunology
ISSN: 2162-4011
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
27 10 2020
27 10 2020
Historique:
entrez:
12
11
2020
pubmed:
13
11
2020
medline:
13
11
2020
Statut:
epublish
Résumé
In September 2020, the Japanese government approved cetuximab saratolacan (previously known as RM-1929, commercial name: Akalux) for the treatment of unresectable locally advanced or recurrent head and neck cancer. Cetuximab saratolacan is a chemical conjugate of the photosensitizer IR700 with cetuximab, which targets EGFR. The treatment consists in the intravenous injection of cetuximab saratolacan, which binds to head and neck cancer cells expressing high levels of EGFR, followed by illumination of the tumor with red light (690 nm) for photodynamic therapy. This approach causes immunogenic cell death in malignant tissues, thus triggering a potent anticancer immune response.
Identifiants
pubmed: 33178498
doi: 10.1080/2162402X.2020.1841393
pii: 1841393
pmc: PMC7595598
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
1841393Informations de copyright
© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.
Références
EMBO J. 2018 Jul 2;37(13):
pubmed: 29807932
Nat Commun. 2018 Apr 12;9(1):1410
pubmed: 29650952
Biochim Biophys Acta Rev Cancer. 2019 Dec;1872(2):188308
pubmed: 31401103
Cancer Immunol Res. 2019 Mar;7(3):401-413
pubmed: 30683733
ACS Cent Sci. 2018 Nov 28;4(11):1559-1569
pubmed: 30555909
Int Immunol. 2021 Jan 1;33(1):7-15
pubmed: 32496557
Cell Death Dis. 2019 Aug 2;10(8):578
pubmed: 31371700
Photochem Photobiol Sci. 2015 Oct;14(10):1765-80
pubmed: 26219737
Nat Rev Clin Oncol. 2020 Jan;17(1):49-64
pubmed: 31595049
EMBO J. 2012 Mar 7;31(5):1062-79
pubmed: 22252128